Abeona buys EoE drug candidate APT-1011, raises $30 million as ZEVASKYN sales growNov 9M&AAbeona Therapeutics, IncEupraxia Pharmaceuticals Inc.Updated
Ultragenyx ends three GTX-102 trials in Angelman syndrome for lack of efficacyNov 3Trial updateapazunersenUltragenyx Pharmaceutical Inc
Ultragenyx settles DOJOLVI patent suit with Navinta over generic ANDAOct 19Regulatory decisiontriheptanoinUltragenyx Pharmaceutical Inc
Ultragenyx agrees to sell rare pediatric priority review voucher for $203 millionOct 14M&AUltragenyx Pharmaceutical Inc
Ultragenyx agrees to sell rare pediatric disease priority review voucher for $210 millionOct 7M&AUltragenyx Pharmaceutical Inc
FDA grants full approval to Ultragenyx gene therapy FAYUVI for Sanfilippo syndrome Type ASep 17Regulatory milestoneUltragenyx Pharmaceutical Inc
Ultragenyx says apazunersen missed both main goals in Phase 3 Angelman syndrome trialSep 2Clinical readoutapazunersenUltragenyx Pharmaceutical Inc
Ultragenyx reports Q2 2026 results, cites two PDUFA dates and Angelman readout aheadAug 4Quarterly updateapazunersenrebisufligene etisparvovec